Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Fat Food Effect on Pexidartinib PK in Healthy Subjects
NCT03901313Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pexidartinib in tenosynovial giant cell tumor (TGCT) (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Observed Concentration in Plasma, Time to Cmax and 3 more. Started Apr 2019; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT03901313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901313.